News

February 24, 2020
AliveCor, the leader in AI-based, personal ECG technology, and provider of enterprise cardiology solutions, announced approval from the Federal Commission for the Protection against Sanitary Risk (COFEPRIS), to launch
February 19, 2020
Abbott announced it has received CE Mark for the new Gallant™ implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices, bringing the most advanced heart rhythm management capabilities along with a new set of benefits to people in Europe with abnormal heart rhythms and heart failure.
February 19, 2020
iSchemaView, also known as RAPID, the worldwide leader in advanced imaging for stroke, announced the company is now RapidAI. In 2018, co-founder Dr. Greg Albers presented groundbreaking findings at the International Stroke Conference (ISC) that supported expanded treatment window guidelines for stroke patients.
February 18, 2020
Acutus Medical announced FDA clearance and CE Mark of SuperMap — a revolutionary addition to its AcQMap 3D Imaging and Mapping System.
February 18, 2020
Itamar Medical Ltd., a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, announced publication of results of the COMPASS study validating scoring guidelines that better enable physicians and respiratory technologists
February 13, 2020
VitalConnect®, Inc., a leader in wearable biosensor technology, announced the introduction of arrhythmia detection to its remote monitoring portfolio. In partnership with CorVitals, Inc., VitalConnect now offers physicians the ability to monitor, diagnose, and treat patients suffering from various heart conditions and diseases.
February 4, 2020
CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced that the company has submitted a pre-market approval (PMA) supplement to the U.S.
February 3, 2020
Chicago-based medical device firm Attune Medical announced the presentation of clinical results from the largest device study to date designed to evaluate the performance of its ensoETM patient temperature management device as an aid in the reduction of esophageal injury during cardiac ablation, a common treatment for atrial fibrillation.
February 3, 2020
Abbott announced that the U.S. Food and Drug Administration (FDA) has approved a new trial designed to assess its Amplatzer™ Amulet™ Left Atrial Appendage Occluder for people with atrial fibrillation (AF) – a condition in which the normal rhythm of the heart's upper chambers is disrupted and becomes erratic – who are at risk of stroke.